

COMMUNITY HEALTH & EDUCATION DIVISION  
FEE SCHEDULE  
Proposed - FY 23-24

Serial Number	CPT Code	CPT Title	22/23 Approved Fees	23/24 Proposed Fees
1	0031A	Administration COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL first dose	37.85	37.85
2	90473	Administration of 1 nasal or oral vaccine	20	20
3	90471	Administration of 1 vaccine	20	20
4	G0010	Administration of hepatitis b vaccine	20	20
5	G0008	Administration of influenza virus vaccine	20	20
6	90474	Administration of nasal or oral vaccine	20	20
7	G0009	Administration of pneumococcal vaccine	20	20
8	90472	Administration of vaccine	20	20
9	S0612	Annual gynecological examination, established patient	150	150
10	99172	Automated or semi-automated visual function screening of both eyes	10	10
11	Q0144	Azithromycin dihydrate, oral, capsules/powder, 1 gram	0	0
12	83986	Body fluid pH level	3	3
13	46900	Chemical destruction of anal growths	365	365
14	54050	Chemical destruction of growths of penis	200	200
15	S4993	Contraceptive pills for birth control	20	20
16	A4267	Contraceptive supply, condom, male, each	0.3	0.3
17	J7303	Contraceptive supply, hormone containing vaginal ring, each	30	30
18	A4269	Contraceptive supply, spermicide (e.g., foam, gel), each	10	10
19	99195	Court Ordered Testing	170	170
20	56515	Destruction of extensive growths of external female genitals	335	335
21	56501	Destruction of external female genital growths	155	155
22	54065	Destruction of multiple penile growths	325	325
23	87273	Detection test for herpes simplex virus type 2	15	15
24	87800	Detection test for multiple organisms	0	0
25	87808	Detection test for Trichomonas vaginal (genital parasite)	16	16
26	87661	Detection test for Trichomonas vaginalis (genital parasite)	11.5	11.5
27	99212	Established patient office or other outpatient visit, typically 10 minutes	60	60
28	99213	Established patient office or other outpatient visit, typically 15 minutes	105	105
29	99211	Established patient office or other outpatient visit, typically 5 minutes	28	28
30	99214	Established patient office or other outpatient, visit typically 25 minutes	150	150
31	99395	Established patient periodic preventive medicine examination age 18-39 years	170	170
32	99396	Established patient periodic preventive medicine examination age 40-64 years	185	185
33	99394	Established patient periodic preventive medicine examination, age 12 through 17 years	165	165
34	99393	Established patient periodic preventive medicine examination, age 5 through 11 years	140	140
35	99397	Established patient periodic preventive medicine examination, age 65 years and older	195	195
36	J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	850	850
37	V5008	Hearing screening	10	10
38	0034A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage; booster dose	37.85	37.85

39	0154A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose	37.85	37.85
40	0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	37.85	37.85
41	0173A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	37.85	37.85
42	0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	37.85	37.85
43	0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	37.85	37.85
44	0124A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose	37.85	37.85
45	0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	37.85	37.85
46	0164A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose	37.85	37.85
47	0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	37.85	37.85
48	0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	37.85	37.85
49	0134A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose	37.85	37.85
50	0144A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose	37.85	37.85

51	0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose	37.85	37.85
52	0042A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose	37.85	37.85
53	90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	0	0
54	99385	Initial new patient preventive medicine evaluation age 18-39 years	185	185
55	99386	Initial new patient preventive medicine evaluation age 40-64 years	215	215
56	99384	Initial new patient preventive medicine evaluation, age 12 through 17 years	190	190
57	99383	Initial new patient preventive medicine evaluation, age 5 through 11 years	160	160
58	99387	Initial new patient preventive medicine evaluation, age 65 years and older	225	225
59	G0402	Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment	305	305
60	96372	Injection beneath the skin or into muscle for therapy, diagnosis, or prevention	35	35
61	J0696	Injection, ceftriaxone sodium, per 250 mg	0	0
62	J1050	Injection, medroxyprogesterone acetate, 1 mg	0.48	0.48
63	11981	Insertion of drug implant, non-biodegradable	200	200
64	36415	Insertion of needle into vein for collection of blood sample	30	30
65	J7300	Intrauterine copper contraceptive	485	485
66	S9443	Lactation classes, non-physician provider, per session	55	55
67	83655	Lead level	15	15
68	J7298	Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 5 year duration	670	670
69	90619	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for IM use	153	153
70	90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB), 2 dose schedule, for intramuscular use	196	196
71	99201	New patient office or other outpatient visit, typically 10 minutes	75	75
72	99202	New patient office or other outpatient visit, typically 20 minutes	115	115
73	99203	New patient office or other outpatient visit, typically 30 minutes	160	160
74	0044A	Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster	37.85	37.85
75	D0191	Oral Assessment of Patient	25	25
76	D0190	Oral Screening of Patient	15	15
77	0174A	Pfizer-BioNTech Covid-19 Bivalent Booster	37.85	37.85
78	58300	Placement of intra-uterine device (IUD) for pregnancy prevention	100	100
79	90677	Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use	0	0
80	90670	Pneumococcal vaccine for injection into muscle	297	297
81	J8499	Prescription drug, oral, non chemotherapeutic, nos	0	0
82	99401	Preventive medicine counseling, approximately 15 minutes	55	55
83	99402	Preventive medicine counseling, approximately 30 minutes	135	135
84	99403	Preventive medicine counseling, approximately 45 minutes	150	150
85	99404	Preventive medicine counseling, approximately 60 minutes	171	171
86	36416	Puncture of skin for collection of blood sample	10	10
87	11982	Removal of drug delivery implant from tissue	225	225
88	11420	Removal of growth (0.5 centimeters or less) of the scalp, neck, hands, feet, or genitals	120	120

89	11421	Removal of growth (0.6 to 1.0 centimeters) of the scalp, neck, hands, feet, or genitals	150	150
90	58301	Removal of intra-uterine device (IUD) for pregnancy prevention	135	135
91	11983	Removal with reinsertion of drug delivery implant into tissue	321	321
92	Q0091	Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory	15	15
93	91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, for intramuscular use	0	0
94	91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0	0
95	91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0	0
96	91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	0	0
97	91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0	0
98	91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0	0
99	91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use	0	0
100	86580	Skin test for tuberculosis	20	20
101	90611	Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection	0	0
102	90611	Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection	0	0
103	87210	Smear for infectious agents	13	13
104	D1206	Topical fluoride varnish;Dental Varnish	30	30
105	81025	Urine pregnancy test	10	10
106	90698	Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for injection into muscle	Market+10%	Market+10%
107	90700	Vaccine for diphtheria, tetanus, and acellular pertussis (whooping cough) injection into muscle, child younger than 7 years	Market+10%	Market+10%
108	90633	Vaccine for Hepatitis A (2 dose schedule) injection into muscle, pediatric or adolescent dosage	Market+10%	Market+10%
109	90632	Vaccine for Hepatitis A injection into muscle, adult dosage	Market+10%	Market+10%
110	90744	Vaccine for Hepatitis B (3 dose schedule) for injection into muscle, pediatric and adolescent patients	Market+10%	Market+10%
111	90739	Vaccine for Hepatitis B adult dosage (2 dose schedule) injection into muscle	Market+10%	Market+10%
112	90746	Vaccine for Hepatitis B adult dosage (3 dose schedule) injection into muscle	Market+10%	Market+10%
113	90651	Vaccine for human papilloma virus (3 dose schedule) injection into muscle	Market+10%	Market+10%
114	90688	Vaccine for influenza administered into muscle to individuals 3 years of age and older	Market+10%	Market+10%

115	90662	Vaccine for influenza for injection into muscle	Market+10%	Market+10%
116	90672	Vaccine for influenza for nasal administration	Market+10%	Market+10%
117	90707	Vaccine for measles, mumps, and rubella (German measles) injection beneath skin	Market+10%	Market+10%
118	90734	Vaccine for meningococcus injection into muscle	Market+10%	Market+10%
119	90732	Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older	Market+10%	Market+10%
120	90713	Vaccine for polio injection beneath the skin or into muscle	Market+10%	Market+10%
121	90675	Vaccine for rabies injection into muscle	Market+10%	Market+10%
122	90681	Vaccine for Rotavirus (2 dose schedule) for oral administration	Market+10%	Market+10%
123	90736	Vaccine for shingles injection beneath skin	Market+10%	Market+10%
124	90714	Vaccine for tetanus and diphtheria toxoids injection into muscle, patient 7 years or older	Market+10%	Market+10%
125	90715	Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older	Market+10%	Market+10%
126	90716	Vaccine for varicella (chicken pox) injection beneath skin	Market+10%	Market+10%
127	82120	Vaginal fluid chemical analysis for bacteria	6	6
128	90750	Zoster (shingles) vaccine (HZV), recombinant, sub-unit, adjuvanted, for intramuscular use	Market+10%	Market+10%